RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $180 from $160 and keeps an Outperform rating on the shares. After a near best-case scenario for competitor Teva (TEVA) price discounting, the firm is adjusting its model accordingly to reflect better net pricing preservation for Ingrezza in the public channel in 2027-2028, as well as the out years, given likely less direct IRA impact, the analyst tells investors in a research note. The firm now expects more stable revenues, with sales peaking at $3.2B in 2030 vs. $3.0B in 2028 and a higher out-year tail, RBC added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $200 from $175 at TD Cowen
- Neurocrine’s Strong Market Position and Growth Potential: Buy Rating Affirmed
- Neurocrine Extends Eiry W. Roberts’ Employment Term
- Neurocrine’s Promising Prospects: Buy Rating Backed by Osavampator’s Success and Ingrezza’s Revenue Growth
- Neurocrine price target lowered to $173 from $178 at Morgan Stanley